|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 10:58AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 11:16AM
|
|
Re: MOA of Apabetalone - only affects sick patients
|
2
|
Resverlogix Corp.
|
Apr 15, 2019 08:46AM
|
|
Re: MOA of Apabetalone - only affects sick patients
|
5
|
Resverlogix Corp.
|
Apr 15, 2019 09:42AM
|
|
Re: NASH is a $35 Billion US/year market
|
1
|
Resverlogix Corp.
|
Dec 31, 2018 07:21PM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:38PM
|
|
Re: New article on BET Inhibitors in Cardiovascular Disease
|
6
|
Resverlogix Corp.
|
Jan 30, 2019 01:30PM
|
|
Re: News
|
5
|
Resverlogix Corp.
|
Aug 12, 2019 06:12PM
|
|
Re: NLRP3 inhibitors and apabetalone
|
6
|
Resverlogix Corp.
|
Jul 26, 2019 01:24PM
|
|
Re: NLRP3 inhibitors and apabetalone
|
5
|
Resverlogix Corp.
|
Jul 26, 2019 01:32PM
|
|
Re: noticed Hepalink hasn't followed the same pattern over the last month..
|
|
Resverlogix Corp.
|
May 09, 2019 10:07AM
|
|
Re: Potential Market Size
|
1
|
Resverlogix Corp.
|
Apr 18, 2019 12:27PM
|
|
Re: Probability of Phase 3 trial success
|
2
|
Resverlogix Corp.
|
Jun 22, 2019 07:52PM
|
|
Re: Publication / Resverlogix An Author
|
5
|
Resverlogix Corp.
|
Aug 21, 2019 06:18AM
|
|
Re: Publication / Resverlogix An Author
|
3
|
Resverlogix Corp.
|
Aug 20, 2019 10:54AM
|
|
Re: Question about Phase 2
|
3
|
Resverlogix Corp.
|
Mar 12, 2019 09:50AM
|
|
Re: Radio Silence
|
1
|
Resverlogix Corp.
|
Jun 03, 2019 04:27PM
|
|
Re: Reata
|
3
|
Resverlogix Corp.
|
Apr 03, 2019 01:57PM
|
|
Re: Reata
|
1
|
Resverlogix Corp.
|
Apr 03, 2019 02:00PM
|
|
Re: Reata Nasdaq Symbol RETA
|
1
|
Resverlogix Corp.
|
May 03, 2019 09:57AM
|
